LITE: Light Therapy to Increase Energy in Adolescents and Young Adults Newly Diagnosed with Solid Tumors: A Pilot Study

Categories:

Psychology

Supportive Solid Tumor Studies

Diseases Treated:

Solid tumors

Eligibility Overview:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

  • At least 12 years old 
  • Diagnosed with a solid tumor or lymphoma within the past 30 days 
  • Speaks, reads and writes in English or Spanish
  • No blindness or history of eye disease including, but not limited to macular degeneration, or other diagnosed retinal problems 
  • Not initiated antidepressant medication, including either SSRIs in the past month, and MAOIs in the past two months
  • No laser corrective eye surgery in the past 30 days

Description

This study will enroll participants who have been diagnosed with a solid tumor. Researchers want to see how likely adolescents and young adults with cancer are to use light therapy as an intervention that may help improve fatigue associated with cancer treatment. Fatigue is one of the most common and upsetting symptoms reported by children, adolescents and young adults receiving cancer treatment. Some data suggest light therapy can help reduce fatigue. The study team would like to see if a particular type of light therapy, Bright White Light (BWL) or Dim Red Light (DRL) is more effective than the other. In this study, BWL and DRL will be compared to each other to determine their effect in reducing fatigue in cancer patients.

Primary Objectives

  • To estimate the feasibility and acceptability of a BWL intervention compared to a DRL standard comparison group in adolescent solid tumor patients. 
  • To estimate the rates of consent to a BWL intervention compared to DRL in adolescent solid tumor patients. 
  • To estimate the rates of adherence to the intervention in adolescent solid tumor patients for each the intervention and comparison groups. 
  • To estimate the rates of side effects in a BWL intervention trial. 

Eligibility Criteria (among others)

  • At least 12 years old 
  • Diagnosed with a solid tumor or lymphoma within the past 30days
  • Speaks, reads and writes in English or Spanish 
  • No blindness or history of eye disease including, but not limited to macular degeneration, or other diagnosed retinal problems 
  • Not initiated antidepressant medication, including either SSRIs in the past month, and MAOIs in the past two months
  • No laser corrective eye surgery in the past 30 days 

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children’s Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).

Principal Investigator

Valerie Crabtree, PhD

St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105  USA
Voice: 1-888-226-4343 or 901-595-4055
24-Hour Emergency Access Pager: 1-800-349-4334
Email: referralinfo@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.